Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous PD1-knockout CD19-specific CAR T cells BRL-201

A preparation of autologous T lymphocytes that are non-virally gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to integrate a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 in the locus of the programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1) gene, with potential immunomodulating and antineoplastic activities. Upon administration, autologous PD1-knockout CD19-specific CAR T cells BRL-201 specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. Expression of PD-1, an inhibitory receptor expressed on activated T cells, plays a key role in cytotoxic T-lymphocyte (CTL) suppression, T-cell exhaustion and CTL apoptosis. PD-1 knockout may abrogate T-cell exhaustion and increase T-cell activity and cytotoxicity.
Synonym:autologous CD19-targeted PD1 site-specific integrated CAR-T cells BRL-201
autologous PD1-knockout anti-CD19-CAR T cells BRL-201
Code name:BRL 201
BRL-201
BRL201
Search NCI's Drug Dictionary